Engineering the Extraordinary - Investor Presentation

Committed to accelerating and sustaining higher growth over the long term Significant changes made and further changes underway; industry-leading technology pipeline coming to fruition Significant transformational efforts to position Medtronic for durable & accelerated innovation-driven growth New operating model and enhanced Medtronic Mindset are leveraging scale and accelerating decision making with incentives aligned to create shareholder value. Expect quarterly acceleration through FY23, driven by resolution of acute supply chain issues, easier comparisons, and new product launches ✓ Advancing scientific evidence and significant near-term catalysts in fast-growing MedTech markets Conducted over 230 clinical trials in FY22; 180 product approvals in last 12 months driving upcoming launches to support accelerated growth profile; Continued investments in mid-term programs to deliver durable growth consistent with long-range plan Committed to Environmental, Social, and Governance Progressing towards goal of becoming operationally carbon neutral by FY30; Continued focus on Patient Safety & Quality, Inclusion Diversity & Equity, Climate Stewardship, and Product Stewardship; published FY22 Integrated Performance Report in October ◉Rigorous portfolio management and capital allocation strategies focused on higher WAMGR and creating shareholder value Portfolio management process is ongoing: Planned separation of Patient Monitoring and Respiratory Interventions business; Renal Care Solutions will be part of NewCo with DaVitaⓇ; Intersect ENT acquisition closed May 2022; Affera acquisition closed August 2022; expanding our commercial solutions via Acutus* and CathWorks* deals. Dividend Aristocrat; returned $5.5B to shareholders through share repurchases and dividends, or 92% of FCF in FY22 * Announced intention to acquire Acutus' Left-Heart Access Portfolio; Signed a co-promote deal with CathWorks with the option to acquire in the future Investor Meetings | November 2022 3 Medtronic

View entire presentation